The Peter Attia Drive

#320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape

70 snips
Oct 7, 2024
Nick Stenson, co-host and health enthusiast, joins the conversation on the rising trend of GLP-1 agonists, including Ozempic and Mounjaro, originally developed for diabetes. They dive into the drugs' efficacy, safety profiles, and surprising side effects, especially when discontinued. The duo also discusses how resistance training can affect weight loss journeys with these medications. Plus, insights on the role of compounding pharmacies and a glimpse into promising treatments on the horizon make for a captivating and informative discussion.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

GLP-1 Agonists Origin

  • GLP-1 agonists, like Ozempic, were first developed for type 2 diabetes management.
  • They mimic GLP-1, a hormone that stimulates insulin release and lowers blood sugar.
INSIGHT

New Insights on GLP-1 Agonists

  • More safety data on GLP-1 agonists is available now, including post-approval surveillance.
  • We also have a better understanding of their long-term efficacy and how they promote weight loss.
INSIGHT

Body Composition and Exercise

  • Studies now include data on body composition changes, not just weight.
  • The role of exercise in weight loss and maintenance is better understood.
Get the Snipd Podcast app to discover more snips from this episode
Get the app